Jennifer McDevitt

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly, Jeeyun Lee, Yung‐Jue Bang et al. · Clinical Cancer Research · 2019 · 126 citations · Full text

Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas

Michael J. Pishvaian, Michael A. Morse, Jennifer McDevitt et al. · Clinical Colorectal Cancer · 2016 · 95 citations

Human Carcinoembryonic Antigen, Gastrointestinal Oncology, Medicine +9

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

Paul Haluska, Michael E. Menefee, Elizabeth R. Plimack et al. · Clinical Cancer Research · 2014 · 60 citations · Full text

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale et al. · Clinical Cancer Research · 2018 · 52 citations · Full text

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

Sattva S. Neelapu, Javier Muñoz, Frederick L. Locke et al. · Journal of Clinical Oncology · 2020 · 46 citations

Clinical Immunology, T Cell Therapy, Adaptive Immune System +27